株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の遺伝子治療市場の見通し

Global Gene Therapy Market Outlook 2020

発行 RNCOS E-Services Pvt. Ltd. 商品コード 312362
出版日 ページ情報 英文 155 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
世界の遺伝子治療市場の見通し Global Gene Therapy Market Outlook 2020
出版日: 2015年09月01日 ページ情報: 英文 155 Pages
概要

世界の遺伝子治療産業は、2020年末までに数百万ドル規模の産業になる可能性を秘めています。

当レポートでは、世界の遺伝子治療市場について調査分析し、産業の動向と促進要因、抑制要因、市場の見通し、規制情勢、主要企業分析などを含めて、体系的な情報を提供しています。

第1章 アナリストの見解

第2章 調査手法

第3章 遺伝子治療:イントロダクション

  • 遺伝子治療技術の分類
  • 遺伝子導入の物理的手法
  • 遺伝子治療用ベクター

第4章 産業の概要

  • 市場促進要因
    • がん治療に対する従来の治療の失敗
    • 先進国における遺伝子治療薬製品化の加速
    • 生命に関わる慢性病の増加
    • ベンチャー投資会社の関心の高まり
  • 市場抑制要因
    • 厳しい規制と安全性に関する懸念
    • 現在の技術にある落とし穴
    • 治療コストの高さ
  • 市場機会
    • 欧州で承認された遺伝子治療薬
    • B型血友病の遺伝子治療で大きなチャンス到来
  • 産業の動向
    • 遺伝子サイレンシング(遺伝子抑制):躍進を遂げる
    • 最先端治療:遺伝子治療と幹細胞技術を組み合わせる
    • 免疫不全症候群:遺伝子治療の中心
    • ナノテクノロジー:遺伝子治療を活性化
    • 遺伝子治療:失明の治療に光明
    • 遺伝子治療:がん治療の潜在性
  • 成功のための規範

第5章 臨床試験評価およびパイプライン分析

  • 臨床試験評価
    • 地域別
    • 適応別
    • 遺伝子タイプ別
    • ベクター別
    • 臨床試験フェーズ別
  • パイプライン分析

第6章 遺伝子治療市場:規制情勢および医療費償還状況

  • 規制情勢
    • 米国
    • カナダ
    • 欧州
    • 日本
    • 中国
    • インド
    • オーストラリア

第7章 市販の遺伝子治療薬

  • Neovasculgen
  • Glybera
  • Gendicine, Rexin-G, Oncorine

第8章 世界の遺伝子治療市場

第9章 用途別遺伝子治療市場

  • 腫瘍
  • 循環器疾患
  • 感染症
  • 神経疾患
  • 遺伝性疾患
  • その他

第10章 世界の遺伝子治療市場規模:地域別

  • 北米
  • 欧州
  • アジア
  • その他の地域

第11章 競合情勢

  • 各企業が採用する戦略
    • 戦略的協力
    • 買収
    • 資金調達・投資
  • 遺伝子治療で飛躍した企業

第12章 主要企業分析(事業内容、臨床パイプライン、最新動向、強みと弱みなど)

  • Spark Therapeutics, LLC
  • ViroMed Co. Ltd. dba VM BioPharma
  • Advantagene Inc
  • Bluebird Bio
  • Sanofi
  • Vical Inc
  • Oxford BioMedica Plc
  • Genethon
  • UniQure N.V.
  • Human Stem Cells Institute
  • Shanghai Sunway Biotech Co. Ltd.
  • Sibiono GeneTech Co. Ltd.

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Gene therapy is a therapeutic technique which replaces damaged proteins in the cell by artificially introducing the DNA into a cell. Majority of the metabolic or genetic disorders are a consequence of either a direct genetic aberration or a dysfunctional/non-functional protein. The attempt to use nucleic acids to correct or erase the genes causing a particular disease is the basis of gene therapy. Despite the fact that gene therapy has not contributed fundamentally to the global pharmaceutical market yet, it is expected to grow at a fast pace over the next decade.

As indicated by the new estimation carried out in our most recent study, the global gene therapy industry can possibly turn into a multi-million dollar industry by the end of 2020, as new products, particularly those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth.

According to RNCOS' new research report "Global Gene Therapy Market Outlook 2020", a major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the gene therapy market, such as phases, geographies, vector types, etc.

The gene therapy market has very few marketed products. The market is majorly in the research phase from which most of its revenue is generated. The report also provides the sales of major marketed gene therapy products and the list of the products in clinical/pre-clinical research along with their clinical phases.

The companies operating in the gene therapy market are also receiving various funding, grants, and investment from government bodies and venture capitalist firms, which are aiding them to develop new products. The study highlights the applications for which the investments have been received.

Primarily, the gene therapy market is dominated by oncology applications with several companies and academic institutions focusing on novel and 'difficult to treat' cancers. Other therapeutic areas seeking developments in gene therapy include monogenic diseases, cardiovascular diseases, infectious diseases, inherited blindness and neurological diseases. The report provides the market analysis of key therapeutic areas along with the forecast till 2020.

North America continues to have the maximum number of clinical trials in the gene therapy segment. This is a major reason for the dominant position of North America in the gene therapy market. Based on the geography, the market is divided into four regions, namely, North America, Europe, Asia and Rest of the World. The report provides the market for each of the geography, along with its forecast till 2020.

RNCOS, in its report, further covers how major trends and drivers, mainly gene silencing, advanced therapies combining gene therapy and stem cell technology, immunodeficiency syndromes, growing interest of venture capital firms, etc. will propel the industry's growth. An analysis has also been done of a few factors limiting the growth of the industry. The report also provides insights regarding the strategies adopted by the players from 2013 to 2015 for enhancing their market share. Finally, with a view to understanding the competitive landscape, the profiles of key market players have been included in the report to present a complete picture of the global gene therapy market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Gene Therapy - An Introduction

  • 3.1 Classification of Gene Therapy Techniques
  • 3.2 Physical Methods of Gene Transfer
    • 3.2.1 Electroporation
    • 3.2.2 Hydrodynamic
    • 3.2.3 Microinjection
    • 3.2.4 Particle Bombardment
    • 3.2.5 Ultrasound-Mediated Transfection
  • 3.3 Vectors for Gene Therapy
    • 3.3.1 Viral Vectors
      • 3.3.1.1 Adenoviral Vectors
      • 3.3.1.2 Adeno-associated Virus Vectors
      • 3.3.1.3 Retroviral Vectors
      • 3.3.1.4 Lentiviral Vectors
    • 3.3.2 Non Viral Vectors
      • 3.3.2.1 Naked DNA/Plasmid Vectors
      • 3.3.2.2 Oligonucleotides
      • 3.3.2.3 Liposomes, Lipoplexes and Polyplexes
      • 3.3.2.4 Gene-Activated Matrix

4. Industry Overview

  • 4.1 Market Drivers
    • 4.1.1 Failure of Conventional Therapies to Treat Cancers
    • 4.1.2 Rising Focus to Accelerate Commercialization of Gene Therapy in Developed Nations
    • 4.1.3 Rising Incidence of Chronic and Life Threatening Diseases
    • 4.1.4 Growing Interest of Venture Capital Firms
  • 4.2 Market Restraints
    • 4.2.1 Stringent Regulatory Laws & Safety Concerns
    • 4.2.2 Pitfalls in Current Technique
    • 4.2.3 High Cost of the Gene Therapy Drugs
  • 4.3 Market Opportunities
    • 4.3.1 Approval of Gene Therapy Drug in Europe
    • 4.3.2 Gene Therapy for Hemophilia B Offers Significant Opportunity
  • 4.4 Industry Trends
    • 4.4.1 Gene Silencing: Gaining Momentum
    • 4.4.2 Advanced Therapies: Combining Gene Therapy and Stem Cell Technology
    • 4.4.3 Immunodeficiency Syndromes: The Focus of Gene Therapy
    • 4.4.4 Nanotechnology: Empowering Gene Therapy
    • 4.4.5 Gene Therapy: A New Hope to Treat Blindness
    • 4.4.6 Gene Therapy: Potential Cure for Cancer
  • 4.5 Winning Imperatives
    • 4.5.1 Investment in R&D Activities

5. Clinical Trial Assessment & Pipeline Analysis

  • 5.1 Clinical Trials
    • 5.1.1 By Geography
    • 5.1.2 By Indication
    • 5.1.3 By Gene Type
    • 5.1.4 By Vector
    • 5.1.5 By Clinical Trial Phase
  • 5.2 Pipeline Analysis

6. Gene Therapy Market - Regulatory Landscape & Reimbursement Scenario

  • 6.1 Regulatory Landscape
    • 6.1.1 US
    • 6.1.2 Canada
    • 6.1.3 Europe
    • 6.1.4 Japan
    • 6.1.5 China
    • 6.1.6 India
    • 6.1.7 Australia
  • 6.2 Reimbursement Scenario in Global Market

7. Marketed Gene Therapies

  • 7.1 Neovasculgen
  • 7.2 Glybera
  • 7.3 Gendicine, Rexin-G, Oncorine
    • 7.3.1 Gendicine
    • 7.3.2 Rexin G
    • 7.3.3 Oncorine

8. Global Gene Therapy Market

9. Gene Therapy Market by Application

  • 9.1 Oncology
  • 9.2 Cardiovascular Diseases
  • 9.3 Infectious Diseases
  • 9.4 Neurological Diseases
  • 9.5 Genetic Diseases
  • 9.6 Others

10. Global Gene Therapy Market Size by Geography

  • 10.1 North America
  • 10.2 Europe
  • 10.3 Asia
  • 10.4 Rest of the World (RoW)

11. Competitive Landscape

  • 11.1 Strategies Adopted by Various Players
    • 11.1.1 Strategic Collaborations
    • 11.1.2 Acquisitions
    • 11.1.3 Funding & Investments
  • 11.2 Companies Progress in Gene Therapy In 2015

12. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses)

  • 12.1 Spark Therapeutics, LLC
  • 12.2 ViroMed Co. Ltd. dba VM BioPharma
  • 12.3 Advantagene Inc.
  • 12.4 Bluebird Bio
  • 12.5 Sanofi
  • 12.6 Vical Inc.
  • 12.7 Oxford BioMedica Plc
  • 12.8 Genethon
  • 12.9 UniQure N.V.
  • 12.10 Human Stem Cells Institute
  • 12.11 Shanghai Sunway Biotech Co. Ltd.
  • 12.12 Sibiono GeneTech Co. Ltd.

List of Figures:

  • Figure 4-1: Global - Venture Capitalist Investments in Gene Threapy Product Development (Billion US$), 1999 to H1 2015
  • Figure 5-1: Global - Number of Approved Gene Therapy Clinical Trials (2005-July 2015)
  • Figure 5-2: Global - Geographical Distribution of Gene Therapy Clinical Trials by Continents till July, 2015
  • Figure 5-3: Global - Geographical Distribution of Gene Therapy Clinical Trials by Countries till July, 2015
  • Figure 5-4: Global - Gene Therapy Clinical Trials by Indication till July, 2015
  • Figure 5-5: Global - Gene Therapy Clinical Trials by Types of Gene Transferred till July, 2015
  • Figure 5-6: Global - Gene Therapy Clinical Trials by Percentage of Vectors Used till July, 2015
  • Figure 5-7: Global - Gene Therapy Clinical Trials by Phase till July, 2015
  • Figure 6-1: US - Number of New Cell Therapy and Gene Therapy Products Submission to FDA (2003-2010)
  • Figure 6-2: Japan - Evaluation System of Gene Therapy Clinical Trial
  • Figure 7-1: Global - Neovasculgen Sales (Million US$), 2013 & 2014
  • Figure 8-1: Global - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-1: Global - Gene Therapy Market by Application (%), 2015
  • Figure 9-2: Global - Gene Therapy Market by Application (%), 2020
  • Figure 9-3: Global - Gene Therapy Oncology Market (Million US$), 2014, 2015 & 2020
  • Figure 9-4: Global - Gene Therapy Oncology Market by Geography (%), 2015
  • Figure 9-5: Global - Gene Therapy Cardiovascular Disease Market (Million US$), 2014, 2015 & 2020
  • Figure 9-6: Global - Gene Therapy Cardiovascular Disease Market by Geography (%), 2015
  • Figure 9-7: Global - Gene Therapy Infectious Disease Market (Million US$), 2014, 2015 & 2020
  • Figure 9-8: Global - Gene Therapy Infectious Disease Market by Geography (%), 2015
  • Figure 9-9: Global - Gene Therapy Neurological Disease Market (Million US$), 2014, 2015 & 2020
  • Figure 9-10: Global - Gene Therapy Neurological Disease Market by Geography (%), 2015
  • Figure 9-11: Global - Gene Therapy Genetic Disease Market (Million US$), 2014, 2015 & 2020
  • Figure 9-12: Global - Gene Therapy Genetic Disease Market, by Geography (%), 2015
  • Figure 9-13: Global - Gene Therapy Other Disease Market (Million US$), 2014, 2015 & 2020
  • Figure 9-14: Global - Gene Therapy Other Disease Market by Geography (%), 2015
  • Figure 10-1: Global - Gene Therapy Market by Geography (%), 2015
  • Figure 10-2: North America - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 10-3: Europe - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 10-4: Asia - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 10-5: Asia - Number of Gene Therapy Laboratories by Major Asian Countries (2014)
  • Figure 10-6: India - Number of Gene Therapy Laboratories (2000, 2010 & 2013)
  • Figure 10-7: Rest of the World - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 11-1: Key Growth Strategies Adopted by Key Players (2013 to 2015)
  • Figure 11-2: Key Players Focusing on Strategic Collaborations (2013 to 2015)
  • Figure 11-3: Key Players Focusing on Strategic Acquisitions (2013 to 2015)
  • Figure 11-4: Key Players Focusing on Funding & Investments (2013 to 2015)
  • Figure 11-5: Companies Progress in Gene Therapy till 2015

List of Tables:

  • Table 4-1: US - Gene Therapies under Development
  • Table 4-2: Europe - Gene Therapies under Development
  • Table 4-3: Gene Therapy Companies Funded by Venture Capital Firms
  • Table 4-4: Current Status of Clinical Trials for Hemophilia
  • Table 5-1: Human Gene Transfer Trials Approved by Condition till 2012
  • Table 5-2: Key Ongoing Gene Therapy Clinical Trials
  • Table 6-1: China - Key Players and their Products in Gene Therapy
  • Table 9-1: Vectors Used for Cardiovascular Gene Transfer
  • Table 12-1: Spark Therapeutics LLC - Clinical Pipeline in Gene Therapy
  • Table 12-2: ViroMed Co. Ltd. - Clinical Pipeline in Gene Therapy
  • Table 12-3: Advantagene Inc. - Clinical Pipeline in Gene Therapy
  • Table 12-4: Bluebird Bio - Clinical Pipeline in Gene Therapy
  • Table 12-5: Sanofi - Clinical Pipeline in Gene Therapy
  • Table 12-6: Vical Inc. - Clinical Pipeline in Gene Therapy
  • Table 12-7: Oxford Biomedica Plc - Clinical Pipeline in Gene Therapy
  • Table 12-8: Genethon - Clinical Pipeline in Gene Therapy
  • Table 12-9: UniQure N.V. - Clinical Pipeline in Gene Therapy
  • Table 12-10: Human Stem Cells Institute - Clinical Pipeline in Gene Therapy
  • Table 12-11: Shanghai Sunway Biotech Co. Ltd. - Clinical Pipeline in Gene Therapy
  • Table 12-12: Sibiono GeneTech Co. Ltd. - Clinical Pipeline in Gene Therapy
Back to Top